Las Vegas, NV -- (SBWIRE) -- 09/21/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.EquityObserver.com issues a special report on the following stocks: Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC), Questcor Pharmaceuticals Inc(NASDAQ:QCOR), Inovio Pharmaceuticals Inc(NYSEMKT:INO), Zalicus Inc(NASDAQ:ZLCS)
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) managed to keep its gain at 24.74% on above-normal volume of 8.02 million shares. The stock settled at $4.74 after floating in a range of $4.67to $5.50. Its latest price was $4.74, reaching market capitalization of $83.97 million. Its 52-week range has been $2.75to $8.18. Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, engages in the development and commercialization of mechanism-targeted drugs to treat human cancers and other serious diseases.
What was the Moving Force behind CYCC On Bullish Run? Read This Research Report on CYCC
Questcor Pharmaceuticals Inc(NASDAQ:QCOR) traded down on a volume of 7.87 million, higher than its standard daily volume. Shares have dropped -8.82% to $55.33. Over the last twelve months, the stock has added 83.46% and faced a best price of $74.76. Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P
Has QCOR Found The Bottom And Ready To Gain Momentum? Find Out Here
Inovio Pharmaceuticals Inc(NYSEMKT:INO) settled -6.44% lower at $2.18 on below-normal volume of 7.72 million shares during the last trading day. The stock has its 12-month high at $3.03 and 52-week low price was $0.44. It traded in a range of $2.16 to $2.36 during the last trading day. Inovio Pharmaceuticals, Inc., together with its subsidiaries, engages in the discovery and development of synthetic vaccines and immune therapies focusing on cancers and infectious diseases.
Why Should Investors Buy INO After the Recent Fall ? Just Go Here and Find Out
Zalicus Inc(NASDAQ:ZLCS) saw its price gain on above-normal volume, as 7.55 million shares changed hands when compared with its average daily volume of 2.15 million shares. The stock was up 3.59% to $0.780. It has fallen over the last 12 months, dropping -4.88% and marked new low $0.43. Zalicus Inc., a biopharmaceutical company, engages in the discovery and development of novel treatments for patients suffering from pain.
Why Should Investors Buy ZLCS After The Recent Gain? Just Go Here and Find Out
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/ employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/disclaimer-2/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)